SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
283continuing from Yahoo: Re: Why KOSN has been hit ? by: frag_bug 06/04/03 11:30hmpa-6/4/2003
282strange, particularly this part...... <i>KOS-862 has shown a DLT now, so scaram(o)uche-6/4/2003
281Fwiw from Yahoo board: Why KOSN has been hit ? by: magnam_pi 06/04/03 07:16 pmmopgcw-6/4/2003
280A phase I clinical trial of BMS-247550 (NSC 71028), an epothilone B derivative, scaram(o)uche-6/4/2003
279Multi-institutional trial of epothilone B analogue (BMS-247550) with or without scaram(o)uche-6/4/2003
278A Randomized Phase II study of epothilone analog BMS-247550 in patients (pts) wiscaram(o)uche-6/4/2003
277A phase II study of the epothilone B analog BMS-247550 in patients (pts) with tascaram(o)uche-6/4/2003
276Phase I and pharmacokinetic (PK) study of the novel epothilone <b>BMS-3107scaram(o)uche-6/4/2003
275Phase I trial of novel epothilone B analog <b>BMS-310705</b> IV q 21scaram(o)uche-6/4/2003
274The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal scaram(o)uche-6/4/2003
273A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatscaram(o)uche-6/4/2003
272Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliscaram(o)uche-6/4/2003
271Heat shock protein inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), iscaram(o)uche-6/4/2003
270Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (ptscaram(o)uche-6/4/2003
269A pharmacokinetically (PK) - pharmacodynamically (PD) guided phase I trial of thscaram(o)uche-6/4/2003
268KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study iscaram(o)uche-6/4/2003
267KOS-862 (epothilone D): A comparison of two schedules in patients with advanced scaram(o)uche-6/4/2003
266>> They fell 24 % today for a total of 1 dollar and 76 cent. The turnover Icebrg-6/3/2003
265NOVEL EPOTHILONE COMPOUNDS AND METHODS FOR MAKING THE SAME Patent Number: Pscaram(o)uche-6/2/2003
264United States Patent 6,569,867 Chu , et al. May 27, 2003 --------------scaram(o)uche-6/2/2003
263Rick >>What happens when Novartis merges with Roche?>> I doubt thaIcebrg-6/2/2003
262(Garren's quote) >> If that happens then it is down to two companies,scaram(o)uche-6/2/2003
261fun stuff (given this sharp decline at a point where the companies are committedscaram(o)uche-6/2/2003
260I bailed in the high $6 range a few months ago, because I didn't see any drituck-6/2/2003
259They fell 24 % today for a total of 1 dollar and 76 cent. The turnover was 11 tiIcebrg-6/2/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News